Search Within

Dana Elizabeth Rathkopf

  1. "2009"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (6)
  2. Genitourinary Oncology Service (6)
  3. Solid Tumor Oncology Division (6)
  4. Hematologic Malignancies, Division of (3)
  5. Radiology, Department of (3)
  6. Biostatistics Service (2)

More Groups

People
  1. Howard Scher (5)
  2. Susan Slovin (3)
  3. Christina Hong (2)
  4. David Solit (2)
  5. Jorge Carrasquillo (2)
  6. Michael Morris (2)

More People

Years
  1. 2009 (6)
Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer (1)
  3. Clinical Cancer Research (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. American Association for Cancer Research (1)
  3. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Rathkopf, D. E.; Chi, K. N.; Vaishampayan, U.; Hotte, S.; Vogelzang, N.; Alumkal, J.; Agrawal, M.; Nydam, T. M.; Fandi, A.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy
    Meeting Abstract

    Fleisher, M.; Danila, D. C.; Leversha, M.; Rathkopf, D.; Slovin, S.; Anand, A.; Koscuiszka, M.; Haqq, C.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Journal Article

    Rathkopf, D.; Dickson, M. A.; Feldman, D. R.; Carvajal, R. D.; Shah, M. A.; Wu, N.; Lefkowitz, R.; Gonen, M.; Cane, L. M.; Dials, H. J.; more...
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium
    Journal Article

    Bradley, D.; Rathkopf, D.; Dunn, R.; Stadler, W. M.; Liu, G.; Smith, D. C.; Pili, R.; Zwiebel, J.; Scher, H.; Hussain, M.
    Cancer (2009)

    Fulltext@MSK | Save